Silo Pharma (NASDAQ: SILO), a developmental-stage biopharmaceutical company, has announced a strategic initiative to explore ibogaine-based therapeutics for traumatic brain injury (TBI) and related neuropsychiatric conditions. The company has filed a provisional U.S. patent application covering compositions and methods using ibogaine and related compounds to treat TBI, PTSD, and associated disorders, as detailed in the press release.
The initiative marks a significant expansion of Silo Pharma's therapeutic focus, which traditionally addresses underserved conditions such as stress-induced psychiatric disorders, chronic pain, and central nervous system (CNS) diseases. The company's portfolio includes programs like SPC-15 for PTSD, SP-26 for fibromyalgia and chronic pain, and preclinical assets targeting Alzheimer's disease and multiple sclerosis. Silo's research is conducted in collaboration with leading universities and laboratories.
Ibogaine, a naturally occurring psychoactive compound derived from the African iboga plant, has shown promise in treating addiction and other neurological conditions. By targeting TBI and PTSD, Silo Pharma aims to address significant unmet medical needs. Traumatic brain injury affects millions globally, often leading to long-term cognitive and psychiatric impairments, while PTSD is a debilitating condition with limited treatment options. The filing of a provisional patent suggests Silo is seeking to protect its intellectual property in this emerging therapeutic area.
The company's strategy is part of a broader trend in psychedelic medicine, where compounds like psilocybin, MDMA, and ibogaine are being investigated for mental health and neurological disorders. Silo's approach combines drug development with innovative delivery systems, which could enhance efficacy and safety. The company's status as a developmental-stage biopharmaceutical and cryptocurrency treasury company adds a unique dimension to its business model.
Investors and stakeholders can follow the latest news and updates on Silo Pharma through the company's newsroom at https://ibn.fm/SILO. The announcement underscores Silo's commitment to addressing complex CNS conditions and leveraging novel therapeutics to improve patient outcomes.
